There is good news for Covid-19 infected patients. Biocon, a leading biotechnology company, said on Monday that it would launch a biologic vaccine Itolizumab for the treatment of moderate to severe corona patients, which would cost around $ 8,000 per vial. The company has reported that it has marketed Itolizumab injection (25 mg / five ml) for emergency use in the country for the treatment of cytokine release syndrome in cases of moderate to severe acute respiratory distress syndrome (ARDS) due to the epidemic. Approval has been received from the Controller General of Indian Medicine (DCGI).
Biocon had earlier told in regulatory information that Itolizumab is the first accepted novel biological medicine anywhere in the world, in which patients suffering from severe complications of corona are treated.
Biocon executive chairman Kiran Mazdar-Shaw said, "Until the medicine comes, we need a life-saving vaccine. I think what we are doing in the world is that we can reuse drugs or make new vaccines for the treatment of this corona." He told that even if we get a vaccine by the end of this year or at the beginning of the coming year, there is no guarantee that there will be no re-infection, there is no guarantee that we are expecting it to work, it will work in the same way. So we need to be prepared.
Also Read-
Corona cases cross 9 lakh mark in India, Know death toll
Russia will introduce Corona vaccine in market by August
Maharashtra has highest corona cases in India, more than 6000 new patients surfaced